Temozolomide
- PDF / 169,341 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 164 Views
1 S
Thrombocytopenia: case report In a retrospective analysis of 21 patients conducted between June 2011 and April 2019, a 62-year-old woman* was described, who developed thrombocytopenia during treatment with temozolomide for prolactinoma. The woman, who had prolactinoma had initially received unspecified standard conventional therapy. However, her tumour progressed. Therefore, she started receiving fractionated stereotactic irradiation in combination with temozolomide chemotherapy at the dose of 75 mg/m2 [route and frequency not stated]. During chemotherapy, she developed haematological toxicity in the form of grade 3 thrombocytopenia [duration of treatment to reaction onset not stated]. Subsequently, the dose of temozolomide was modified [outcome not stated]. * Identified patient’s demographic details have been obtained through direct communication with the author. Minniti G, et al. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas. Journal of Neuro-Oncology 149: 803503726 123-130, No. 1, Aug 2020. Available from: URL: http://doi.org/10.1007/s11060-020-03579-5
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
